Novel agents for the treatment of resistant Gram-positive infections (Q35056042)

6 August 2017

1 reference

title

Novel agents for the treatment of resistant Gram-positive infections (English)

1 reference

6 August 2017

gram-positive bacteria

0 references

1

Neil Woodford

1 reference

PubMed ID

12556209

6 August 2017

language of work or name

English

0 references

publication date

1 February 2003

1 reference

Expert Opinion on Investigational Drugs

6 August 2017

1 reference

6 August 2017

12

1 reference

6 August 2017

117-137

1 reference

6 August 2017

2

1 reference

Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

6 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

Molecular analysis of streptogramin resistance in enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

Mechanisms of resistance to quinupristin-dalfopristin among isolates of Enterococcus faecium from animals, raw meat, and hospital patients in Western Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

Linezolid resistance in a clinical isolate of Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

Daptomycin: a novel agent for Gram-positive infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

Development of daptomycin for gram-positive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

D-Ala-D-Ala ligases from glycopeptide antibiotic-producing organisms are highly homologous to the enterococcal vancomycin-resistance ligases VanA and VanB

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

Resistance studies with daptomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

21 January 2018

Glycopeptide derivatives

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

Epidemiology of the genetic elements responsible for acquired glycopeptide resistance in enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

N-alkyl-substituted glycopeptide antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

Deconstructing vancomycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

Effect of growth phase and pH on the in vitro activity of a new glycopeptide, oritavancin (LY333328), against Staphylococcus aureus and Enterococcus faecium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

In vitro evaluation of BI 397, a novel glycopeptide antimicrobial agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

Inhibition of peptidoglycan biosynthesis by ramoplanin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

Rethinking ramoplanin: the role of substrate binding in inhibition of peptidoglycan biosynthesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

Functional analysis of the lipoglycodepsipeptide antibiotic ramoplanin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

In vitro activities of ramoplanin and four glycopeptide antibiotics against clinical isolates of Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococi, enterococci and Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

Effective suppression of vancomycin-resistant Enterococcus species in asymptomatic gastrointestinal carriers by a novel glycolipodepsipeptide, ramoplanin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

Therapies in development for community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

Mutations in the interdomain loop region of the tetA(A) tetracycline resistance gene increase efflux of minocycline and glycylcyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

Mutations in the tetA(B) gene that cause a change in substrate specificity of the tetracycline efflux pump

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

In vitro activity of cephalosporin RWJ-54428 (MC-02479) against multidrug-resistant gram-positive cocci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

Ketolides in the treatment of respiratory infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

In vitro evaluation of AZD2563, a new oxazolidinone, tested against unusual gram-positive species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

In vitro antibacterial activities of DQ-113, a potent quinolone, against clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

Peptide deformylase as a target for new generation, broad spectrum antimicrobial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

Peptide deformylase: a target for novel antibiotics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

Deformylase as a novel antibacterial target.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

Organellar peptide deformylases: universality of the N-terminal methionine cleavage mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

Identification of eukaryotic peptide deformylases reveals universality of N-terminal protein processing mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

The bacterial cell wall as a source of antibacterial targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

Low frequencies of resistance among Staphylococcus and Enterococcus species to the bactericidal DNA polymerase inhibitor N(3)-hydroxybutyl 6-(3'-ethyl-4'-methylanilino) uracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

Novel streptogramin antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

Lantibiotics produced by lactic acid bacteria: structure, function and applications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

Inhibitors of bacterial two-component signalling systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

Glycopeptide antibiotics and development of inhibitors to overcome vancomycin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

Virulence as a target for antimicrobial chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

Quorum sensing: an emerging target for antibacterial chemotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

Prospects for antisense agents in the therapy of bacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

Peptide nucleic acids as antibacterial agents via the antisense principle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

Restoration of vancomycin susceptibility in Enterococcus faecalis by antiresistance determinant gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

21 January 2018

Bacteriophage therapy

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.117

10.1517/13543784.12.2.117

21 January 2018

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12556209